J. Shih

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response

Yih-Leong Chang, J. Shih, Yeun-Chung Chang, 2008, Clinical Cancer Research.

Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.

J. Shih, Chong-Jen Yu, Kuan-Yu Chen, 2018, Lung cancer.

Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma

J. Shih, Yi-nan Liu, C. Gow, 2021, Cancers.

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Sung Sook Lee, J. Shih, T. Hsia, 2022, The oncologist.

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2018, Journal of Cancer.

Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma

J. Shih, Chih-Hsin Yang, Pan‐Chyr Yang, 2010, Medical oncology.

Frequent EGFR mutations in malignant pleural effusion of lung adenocarcinoma

Yih-Leong Chang, J. Shih, Chih-Hsin Yang, 2008 .

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

J. Shih, C. Gow, P-C. Yang, 2008, European Respiratory Journal.

Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression

Wei-Chung Cheng, J. Shih, M. Hung, 2020, Theranostics.

Best Response According to RECIST During First‐line EGFR‐TKI Treatment Predicts Survival in EGFR Mutation‐positive Non–Small‐cell Lung Cancer Patients

Jih-Hsiang Lee, J. Shih, J. Yang, 2018, Clinical lung cancer.

Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial

J. Shih, V. Miller, Chun-Ming Tsai, 2008 .

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.

You Won Lee, Jae Woo Choi, J. Shih, 2018, Cancer research.

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

J. Shih, S. Peters, G. Chang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary mediastinal large B-cell lymphoma mimicking liposarcoma

J. Shih, W. Huang, P. Yang, 2008, Medical oncology.

A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

J. Shih, S. Ou, V. Miller, 2010 .

Response to Stephane Renaud et al.

J. Shih, Chao-Chi Ho, F. Hsu, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report

Yih-Leong Chang, J. Shih, Yeun-Chung Chang, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

J. Shih, Chong-Jen Yu, Chao-Chi Ho, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma.

J. Shih, Chong-Jen Yu, Kuan-Yu Chen, 2017, Journal of Thoracic Oncology.

Leg pains, clubbing of digits and lung mass: What is your call?

J. Shih, Jenn-Yu Wu, 2008, Canadian Medical Association Journal.

Pyomyositis due to Mycobacterium haemophilum in a patient with polymyositis and long-term steroid use.

J. Shih, P. Hsueh, K. Luh, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

New Aspects in Clinicopathologic and Oncogene Studies of 23 Pulmonary Lymphoepithelioma-Like Carcinomas

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2002, The American journal of surgical pathology.

Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan

J. Shih, T. Hsia, J. Hung, 2022, Journal of Cancer.

Pleurocutaneous fistula after tube thoracostomy: Sonographic findings

J. Shih, Yung‐Chie Lee, Pan‐Chyr Yang, 2008, Journal of clinical ultrasound : JCU.

Esteya , a new nematophagous genus from Taiwan, attacking the pinewood nematode ( Bursaphelenchus xylophilus )

J. Shih, S. Tzean, J. Liou, 1999 .

Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma.

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2000, Lung cancer.

The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.

J. Shih, King-Jen Chang, M. Hung, 2006, Cancer cell.

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.

Yih-Leong Chang, J. Shih, J. Yang, 2017, The Lancet. Respiratory medicine.

Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma

Jie Yang, Jih-Hsiang Lee, J. Shih, 2022, Therapeutic advances in medical oncology.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.

J. Shih, Chao-Chi Ho, Hsin-Yi Wang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Extensive GI tract involvement of Ewing's sarcoma/peripheral primitive neuroectodermal tumor in an octogenarian.

J. Shih, Pan‐Chyr Yang, Yu-Ting Chang, 2008, Gastrointestinal endoscopy.

Real-world insights into patients with advanced NSCLC and MET alterations

J. Shih, D. Carbone, E. Smit, 2021, Lung cancer.

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

J. Shih, Keunchil Park, S. Novello, 2019, Journal of Clinical Oncology.

Tracheal botryomycosis in a patient with tracheopathia osteochondroplastica.

J. Shih, P. Hsueh, K. Luh, 1998, Thorax.

Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis

J. Shih, J. Tjiu, C. Chu, 2004, The British journal of dermatology.

Toll-like receptor and matrix metalloproteinase single nucleotide polymorphisms, haplotypes and polygenic risk score differentiated between tuberculosis disease and infection.

J. Shih, Chong-Jen Yu, Meng-Rui Lee, 2022, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Dual energy CT image prediction on primary tumor of lung cancer for nodal metastasis using deep learning

Ruey-Feng Chang, Yeun-Chung Chang, Chii-Jen Chen, 2021, Comput. Medical Imaging Graph..

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.

J. Shih, Ya-Fang Chen, Pan‐Chyr Yang, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer

J. Shih, Pan‐Chyr Yang, J. Yang, 2014, Journal of Thoracic Oncology.

Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.

Yih-Leong Chang, J. Shih, Chong-Jen Yu, 2022, Journal of the Formosan Medical Association = Taiwan yi zhi.

Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2012, BMC Cancer.

Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study

J. Shih, I. Chong, Chong-Jen Yu, 2021, Journal of fungi.

Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.

Sheng-Chieh Hsu, Jin-Yuan Shih, G. Hortobagyi, 2007, Cancer research.

BMVC test, an improved fluorescence assay for detection of malignant pleural effusions

J. Shih, P. Lou, Ta-Chau Chang, 2014, Cancer medicine.

Identification of a Novel Biomarker, SEMA5A, for Non–Small Cell Lung Carcinoma in Nonsmoking Women

Chuhsing Kate Hsiao, Tzu-Pin Lu, Liang-Chuan Lai, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.

J. Shih, J. Yang, Jin-Shing Chen, 2019, European journal of cancer.

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

A. Drilon, M. Okada, S. Ou, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases

J. Shih, J. Yang, K. Lan, 2015, PloS one.

MicroRNA in Lung Cancer Metastasis

J. Shih, Yi-nan Liu, Shang-Gin Wu, 2019, Cancers.

Survival of lung adenocarcinoma patients with malignant pleural effusion

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2012, European Respiratory Journal.

Collapsin response mediator protein-1: A novel invasion-suppressor gene

Chi-Ying F. Huang, J. Shih, Pan‐Chyr Yang, 2003, Clinical & Experimental Metastasis.

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

Jeremy J. W. Chen, J. Shih, T. Hsia, 2015, PloS one.

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.

J. Shih, C. Gow, Shang-Gin Wu, 2017, Lung cancer.

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2008, Clinical Cancer Research.

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

J. Shih, Shang-Gin Wu, 2018, Molecular Cancer.

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

Jin-Yuan Shih, J. Shih, Pan‐Chyr Yang, 2005, The New England journal of medicine.

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2016, Scientific Reports.

Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.

Jeremy J. W. Chen, Ker-Chau Li, Y. Lai, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

J. Shih, Yeun-Chung Chang, Pan‐Chyr Yang, 2011, Clinical Cancer Research.

Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs

J. Shih, Chong-Jen Yu, Lih-Yu Chang, 2020, Frontiers in Oncology.

Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma

J. Shih, Chong-Jen Yu, Hsing-Chen Tsai, 2019, bioRxiv.

EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway

J. Shih, Pan‐Chyr Yang, Shang-Gin Wu, 2015, Scientific Reports.

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

J. Shih, Pan‐Chyr Yang, J. Yang, 2013, Cancer letters.

Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case

Yih-Leong Chang, J. Shih, C. Gow, 2014, Medical Oncology.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

J. Shih, L. Sequist, S. Ou, 2012, The Lancet. Oncology.

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2019, European journal of cancer.

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2016, Oncotarget.

DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non–Small Cell Lung Cancers

Yih-Leong Chang, J. Shih, Wei-Jan Huang, 2015, Clinical Cancer Research.

DUSP 1 Expression Induced by HDAC 1 Inhibition Mediates Ge fi tinib Sensitivity in Non – Small Cell Lung Cancers

Yih-Leong Chang, J. Shih, Wei-Jan Huang, 2015 .

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway

J. Shih, Yi-nan Liu, C. Gow, 2020, Molecular therapy. Nucleic acids.

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2017, ERJ Open Research.

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer

J. Shih, Jenn-Yu Wu, 2016, OncoTargets and therapy.

Brain Metastasis of Patients with Lung Adenocarcinoma: Epidermal Growth Factor Receptor Mutations and Response to Whole-Brain Radiation Therapy

J. Shih, Shang-Gin Wu, 2014 .

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis

Yih-Leong Chang, J. Shih, Yung‐Chie Lee, 2012, European Respiratory Journal.

Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR

J. Shih, Pan‐Chyr Yang, J. Yang, 2012, Clinical Cancer Research.

Frequent EGFR Mutations in NSCLC Presenting with Miliary Intrapulmonary Carcinomatosis

Yih-Leong Chang, J. Shih, Yeun-Chung Chang, 2012 .

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2011, PloS one.

RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer

J. Shih, K. Su, S-L Yu, 2011, European Respiratory Journal.

Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations.

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2011, Lung cancer.

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

J. Shih, Shih-Chieh Chang, Cheng-Yu Chang, 2011, Cancers.

Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.

Meng-Feng Tsai, Chong-Jen Yu, Jin-Yuan Shih, 2008, The oncologist.

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R

Yih-Leong Chang, J. Shih, Chong-Jen Yu, 2005, PLoS medicine.

An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study

J. Shih, Yuh-Min Chen, T. Hsia, 2022, JTO Clinical and Research Reports.

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

J. Shih, Chong-Jen Yu, Meng-Rui Lee, 2021, Frontiers in Oncology.

Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2V659E Mutation.

J. Shih, Ling-Kai Chang, 2020, JCO precision oncology.

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2006, International journal of cancer.

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

J. Shih, Jin-Shing Chen, Chia‐Chi Lin, 2017, The oncologist.

Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer

J. Shih, Yi-nan Liu, C. Gow, 2018, Neoplasia.

Cyclooxygenase-2 Induces EP1- and HER-2/Neu-Dependent Vascular Endothelial Growth Factor-C Up-Regulation

J. Shih, M. Yen, Y. Jeng, 2004, Cancer Research.

Adenocarcinoma Novel Mechanism of Lymphangiogenesis in Lung Vascular Endothelial Growth Factor-C Up-Regulation : Aand HER-2 / Neu-Dependent 1 Cyclooxygenase-2 Induces

J. Shih, M. Yen, Y. Jeng, 2004 .

Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.

J. Shih, Sung-Liang Yu, Pan‐Chyr Yang, 2011, American journal of respiratory and critical care medicine.

The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers.

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2005, The Journal of thoracic and cardiovascular surgery.

The EMT regulator slug and lung carcinogenesis.

J. Shih, Pan‐Chyr Yang, 2011, Carcinogenesis.

Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2021, Cancer letters.

Tumor-associated antigen L6 and the invasion of human lung cancer cells.

J. Shih, Y. Chu, Pan‐Chyr Yang, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.

J. Shih, Chong-Jen Yu, Jenn-Yu Wu, 2019, Clinical lung cancer.

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.

Yeun-Chung Chang, Jin-Yuan Shih, Yih-Leong Chang, 2011, Lung cancer.

Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2011, Medicine.

Predictive Biomarkers and Personalized Medicine Effectiveness of Tyrosine Kinase Inhibitors on " Uncommon " Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non – Small Cell Lung Cancer

J. Shih, Yeun-Chung Chang, Pan‐Chyr Yang, 2011 .

Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2010, International journal of cancer.

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

J. Shih, Yeun-Chung Chang, Y. Chiu, 2008, American journal of respiratory and critical care medicine.

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation

J. Shih, J. Yang, Chong-Jen Yu, 2020, Therapeutic advances in medical oncology.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor‐sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small‐cell Lung Cancer

J. Shih, J. Yang, Yi-nan Liu, 2017, Clinical lung cancer.

Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.

Yih-Leong Chang, J. Shih, Yeun-Chung Chang, 2012, Chest.

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

W. Pao, J. Shih, Yeun-Chung Chang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Pemetrexed‐Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.

J. Shih, J. Yang, Chong-Jen Yu, 2015, Lung cancer.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.

J. Shih, Chia-Lang Hsu, Yi-nan Liu, 2020, Cancer biomarkers : section A of Disease markers.

Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.

J. Shih, J. Yang, J. Ko, 2019, Lung cancer.

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

Jih-Hsiang Lee, J. Shih, Yeun-Chung Chang, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI

J. Shih, Jim-Min Fang, Yuntao Lin, 2018, Oncogene.

Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.

Yih-Leong Chang, J. Shih, Sung-Liang Yu, 2017, Cancer letters.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Cheng-Ta Yang, Chun-Ming Tsai, Chun-Liang Lai, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.

J. Shih, Pan‐Chyr Yang, Ching-Yao Yang, 2021, Lung cancer.

Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan

J. Shih, Sung-Liang Yu, Chong-Jen Yu, 2020, JTO clinical and research reports.

Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.

J. Shih, Yi-nan Liu, Chong-Jen Yu, 2020, Lung cancer.

Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer.

J. Shih, Chong-Jen Yu, Chung-Yu Chen, 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer

J. Shih, J. Yang, A. Cheng, 2018, Clinical and translational radiation oncology.

Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

J. Shih, Yen-Fu Chen, Chong-Jen Yu, 2019, BMC Cancer.

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer

J. Shih, Yi-nan Liu, Yen-Ting Lin, 2019, Front. Oncol..

Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.

J. Shih, Chong-Jen Yu, Lih-Yu Chang, 2019, European journal of cancer.

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Jih-Hsiang Lee, J. Shih, J. Yang, 2019, International journal of cancer.

Clinical Outcome and Toxicity Predictors of Thoracic Re-irradiation for Locoregionally Recurrent Lung Cancer

J. Shih, A. Cheng, S. Kuo, 2018, International Journal of Radiation Oncology, Biology, Physics.

Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?

J. Shih, M. Tsai, Chong-Jen Yu, 2018, European journal of cancer.

Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma.

J. Shih, Pan‐Chyr Yang, Yi-nan Liu, 2016, JAMA oncology.

Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion

J. Shih, J. Yang, Yi-nan Liu, 2018, Genes, chromosomes & cancer.

Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.

J. Shih, Chong-Jen Yu, K. Chung, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Jih-Hsiang Lee, J. Shih, J. Yang, 2020, JTO clinical and research reports.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Jih-Hsiang Lee, J. Shih, J. Yang, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Jih-Hsiang Lee, J. Shih, Yeun-Chung Chang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach

Jie Yang, M. Salto‐Tellez, J. Shih, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

J. Shih, T. Mok, G. Chen, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Octogenarians with Advanced Non-small Cell Lung Cancer: Treatment Modalities, Survival, and Prognostic Factors

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.

J. Shih, Pan‐Chyr Yang, K. Yeh, 2009, Lung cancer.

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer

J. Shih, Chiun Hsu, G. Chang, 2006, Cancer.

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.

J. Shih, C. Gow, P-C. Yang, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

J. Shih, Keunchil Park, L. Paz-Ares, 2021, Clinical Cancer Research.

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

J. Shih, C. Liam, Shun Lu, 2021, Advances in Therapy.

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

J. Shih, Shang-Gin Wu, Chao-Chi Ho, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer

J. Shih, Chia-Wei Chou, Yu-Chih Yang, 2015, Oncotarget.

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas

J. Shih, Yi-nan Liu, C. Gow, 2019, Cancers.

Cardiac involvement in malignancies. Case 1. Favorable outcome of a patient with cardiac invasion from non-small-cell lung carcinoma.

Yih-Leong Chang, J. Shih, Shyr-Chyr Chen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer in pregnancy: report of two cases.

J. Shih, P. Yang, H. C. Wang, 1998, Journal of the Formosan Medical Association = Taiwan yi zhi.

Detection and Quantitation of Circulating Cancer Cells in the Peripheral Blood of Lung Cancer Patients1

J. Shih, Y. Sher, K. Peck, 1998 .

Pericardial pigtail knotting.

J. Shih, Shang-Gin Wu, 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

The Prognostic Value of the Simplified Comorbidity Score in the Treatment of Small Cell Lung Carcinoma

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2011, Journal of Thoracic Oncology.

Knockdown of contactin-1 expression suppresses invasion and metastasis of lung adenocarcinoma.

J. Shih, Y. Jeng, Pan‐Chyr Yang, 2006, Cancer research.

Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non–Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum

J. Shih, Yuh-Min Chen, G. Chang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan

J. Shih, T. Hsia, G. Chang, 2020, Frontiers in Oncology.

Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study

J. Shih, Yi-nan Liu, C. Gow, 2023, Frontiers in Oncology.

Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas

J. Shih, J. Yang, A. Cheng, 2013, Journal of Neuro-Oncology.

Significant Clinical Factors Associated with Long-term Mortality in Critical Cancer Patients Requiring Prolonged Mechanical Ventilation

J. Shih, Yen-Fu Chen, Huey-Dong Wu, 2017, Scientific Reports.

NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.

A. Drilon, J. Shih, R. Doebele, 2019, Journal of Clinical Oncology.

Transcription Repressor Slug Promotes Carcinoma Invasion and Predicts Outcome of Patients with Lung Adenocarcinoma

Jeremy J. W. Chen, Yih-Leong Chang, J. Shih, 2005, Clinical Cancer Research.

Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.

J. Shih, Y. Sher, Y. Chu, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel

J. Shih, C. Kuo, Han-Chun Kuo, 2021, PloS one.

Tumor-Associated Macrophage: Its Role in Cancer Invasion and Metastasis

Jeremy J. W. Chen, J. Shih, A. Yuan, 2006 .

Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells.

Yih-Leong Chang, J. Shih, J. J. Chen, 2001, Journal of the National Cancer Institute.

Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure.

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2002, Journal of the Formosan Medical Association = Taiwan yi zhi.

Subsequent Antituberculous Treatment May Not Be Mandatory Among Surgically Resected Culture-Negative Pulmonary Granulomas: A Retrospective Nationwide Multicenter Cohort Study

J. Shih, I. Chong, Chong-Jen Yu, 2021, Open Forum Infectious Diseases.

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

J. Shih, J. Yang, Chia‐Chi Lin, 2015, Therapeutic advances in medical oncology.

Effects of exercise training on exercise capacity in patients with non-small cell lung cancer receiving targeted therapy

J. Shih, Y. Wu, Pan‐Chyr Yang, 2012, Supportive Care in Cancer.

Osteomyelitis and tenosynovitis due to Mycobacterium marinum in a fish dealer.

J. Shih, M. T. Chen, P. Hsueh, 1997, Journal of the Formosan Medical Association = Taiwan yi zhi.

Tuberculous myositis: a rare but existing clinical entity

J. Shih, P. Hsueh, P. Yang, 2003 .

Global analysis of gene expression in invasion by a lung cancer model.

J. Shih, J. J. Chen, Y. Sher, 2001, Cancer research.

Stage Shift Improves Lung Cancer Survival: A Real-world Evidence

J. Shih, Hsuan-Yu Chen, Pan‐Chyr Yang, 2022, Journal of Thoracic Oncology.

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Jou-Wei Lin, Chong-Jen Yu, Jin-Yuan Shih, 2011, Lung cancer.

Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression

Jeremy J. W. Chen, Yih-Leong Chang, J. Shih, 2017, Oncotarget.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

J. Shih, J. Yang, Chong-Jen Yu, 2013, Clinical lung cancer.

Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients

J. Shih, C. Chiu, R. Perng, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2011, Annals of Surgical Oncology.

Coinfection with Mycobacterium tuberculosis and pandemic H1N1 influenza A virus in a patient with lung cancer.

J. Shih, C. Hung, Li‐Na Lee, 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis.

J. Shih, Pan‐Chyr Yang, J. Yang, 2015, Journal of geriatric oncology.

Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for Small Pulmonary Lesions with Ground-Glass Attenuation

J. Shih, Yeun-Chung Chang, Hon-Man Liu, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer

Yih-Leong Chang, J. Shih, Yi-nan Liu, 2019, International journal of cancer.

Targeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer

Wing-Kai Chan, Ang Yuan, Yu-Chih Chao, 2007, Clinical Cancer Research.

EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2011, Annals of Surgical Oncology.

Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One.

J. Shih, Yen-Ting Lin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary resistance to osimertinib despite acquired T790M

Yih-Leong Chang, J. Shih, Ling-Kai Chang, 2020, Respirology case reports.

Comparable clinical outcomes in patients with HER2‐mutant and EGFR‐mutant lung adenocarcinomas

J. Shih, Jin-Shing Chen, C. Gow, 2017, Genes, chromosomes & cancer.

Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy.

J. Shih, Pan‐Chyr Yang, J. Yang, 2013, Lung cancer.

Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension

Yih-Leong Chang, Mong-Wei Lin, J. Shih, 2014, Journal of surgical oncology.

Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.

Chong-Jen Yu, Jin-Yuan Shih, J. Shih, 2016, Clinical lung cancer.

Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors

Yih-Leong Chang, J. Shih, Ching-Yao Yang, 2020, OncoTargets and therapy.

Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.

A. Drilon, M. Kris, P. Jänne, 2016 .

IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer

J. Shih, Hsuan-Yu Chen, Sung-Liang Yu, 2015, Oncotarget.

Efficacy and Safety of Cone-Beam Computed Tomography-Derived Augmented Fluoroscopy Combined with Endobronchial Ultrasound in Peripheral Pulmonary Lesions

J. Shih, Ching-Kai Lin, J. Ko, 2021, Respiration.

Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2012, BMC Cancer.

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.

J. Shih, Chiun Hsu, Pan‐Chyr Yang, 2008, Lung cancer.

Multi‐kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin‐related protein 1

Yih-Leong Chang, Mong-Wei Lin, J. Shih, 2020, Molecular oncology.

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials

J. Shih, M. Kudo, Sang-We Kim, 2018, Journal of global oncology.

Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.

M. Socinski, J. Shih, F. Shepherd, 2018, Lung cancer.

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.

J. Shih, Meng-Rui Lee, J. Ko, 2017, Oncotarget.

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2020, The oncologist.

Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer.

J. Shih, Chong-Jen Yu, Chih‐Hsin Yang, 2010, Journal of the Formosan Medical Association = Taiwan yi zhi.

A deep learning model using chest X-ray for identifying TB and NTM-LD patients: a cross-sectional study

J. Shih, Po-Chih Kuo, Chong-Jen Yu, 2023, Insights into Imaging.

Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation

J. Shih, Chong-Jen Yu, Ching-Yao Yang, 2021, Biomedicines.

Expression of Notch Gene and Its Impact on Survival of Patients with Resectable Non-small Cell Lung Cancer

J. Shih, Chong-Jen Yu, Chao-Chi Ho, 2017, Journal of Cancer.

Estrrogen receptor ß—which one and where should we draw the line—reply

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2006 .

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.

J. Shih, Yi-nan Liu, C. Gow, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Elevated serum levels of mucin-associated antigen in patients with acute respiratory distress syndrome.

J. Shih, S. C. Yang, R. Wu, 1997, American journal of respiratory and critical care medicine.

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

J. Shih, Meng-Rui Lee, J. Ko, 2017, Oncotarget.

Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

J. Shih, Pan‐Chyr Yang, Jenq-Wen Huang, 2015, Clinical lung cancer.

NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry

A. Drilon, J. Shih, R. Doebele, 2019, Lung cancer.

Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.

J. Shih, Pan‐Chyr Yang, Chong-Jen Yu, 2010, Clinical lung cancer.

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.

J. Shih, C. Chiu, Kang-Yun Lee, 2021, European journal of cancer.

The Long-Term and Mediating Effects of Mindfulness Integrated with Body-Mind-Spirit Group Therapy on Depressive Symptoms and Quality of Life Among Non-small Cell Lung Cancer Patients

J. Shih, Yu-Ting Chen, Feng-Ying Huang, 2021, Mindfulness.

Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life

J. Shih, Chong-Jen Yu, Feng-Ying Huang, 2020, Psychology and Health.

Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR

J. Shih, Yi-nan Liu, C. Gow, 2023, International journal of cancer.

Mice Deficient in Collapsin Response Mediator Protein-1 Exhibit Impaired Long-Term Potentiation and Impaired Spatial Learning and Memory

J. Shih, Shu-Wha Lin, W. Fu, 2007, The Journal of Neuroscience.

The Predictive Value of Transthoracic Shear-Wave Ultrasound Elastography in Differentiating Benign from Malignant Lung Tumors

J. Shih, Huey-Dong Wu, Y. Kuo, 2019, A110. NOVEL IMAGING FOR LUNG CANCER: A PICTURE IS WORTH A THOUSAND WORDS.

Detecting small pulmonary nodules with spiral ultrashort echo time sequences in 1.5 T MRI

J. Shih, Yeun-Chung Chang, M. Su, 2020, Magnetic Resonance Materials in Physics, Biology and Medicine.

Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unit

J. Shih, Yen-Fu Chen, Chong-Jen Yu, 2017, Journal of Cancer.

The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer

J. Shih, Ching-Kai Lin, Chia-Lin Hsu, 2018, Scientific Reports.

Significant Clinical Factors Associated with Long-term Mortality in Critical Cancer Patients Requiring Prolonged Mechanical Ventilation

J. Shih, I. Chen, Yen-Fu Chen, 2017, Scientific Reports.

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

J. Shih, C. Chiu, T. Hsia, 2023, Targeted Oncology.

MiR‐503 pleiotropically regulates epithelial‐mesenchymal transition and targets PTK7 to control lung cancer metastasis

J. Shih, Yi-nan Liu, K. Su, 2023, Cancer medicine.

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.

J. Shih, Chiun Hsu, Pan‐Chyr Yang, 2005, Journal of the Formosan Medical Association = Taiwan yi zhi.

Miliary Pulmonary Nodules: An Unusual Presentation of Leptospirosis.

J. Shih, Chong-Jen Yu, Ching-Yao Yang, 2018, American journal of respiratory and critical care medicine.

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.

Yih-Leong Chang, J. Shih, Chong-Jen Yu, 2005, PLoS medicine.

Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.

J. Shih, J. Yang, Hsu Wu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Deep learning with test-time augmentation for radial endobronchial ultrasound image differentiation: a multicentre verification study

J. Shih, Po-Chih Kuo, Chong-Jen Yu, 2023, BMJ open respiratory research.

Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.

Jie Yang, J. Shih, Pan‐Chyr Yang, 2023, European journal of cancer.

The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer

J. Shih, Ching-Kai Lin, Chia-Lin Hsu, 2018, Scientific Reports.

Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study

J. Shih, Meng-Rui Lee, J. Ko, 2018, Oncotarget.

The EMT regulator slug and lung carcinogenesis.

J. Shih, Pan‐Chyr Yang, 2011, Carcinogenesis.

G. Hortobagyi, J. Shih, M. Hung, 2007, Cancer research.

Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis.

J. Shih, Y. Jeng, Pan‐Chyr Yang, 2004, Journal of the National Cancer Institute.

Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients

J. Shih, Chong-Jen Yu, Meng-Rui Lee, 2023, Cancer medicine.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

J. Shih, J. Yang, Chong-Jen Yu, 2013, Clinical lung cancer.

BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.

J. Shih, A. Italiano, C. Basson, 2021 .

LncRNA SLCO4A1-AS1 suppresses lung cancer progression by sequestering the TOX4-NTSR1 signaling axis

J. Shih, Yi-nan Liu, Shang-Gin Wu, 2023, Journal of Biomedical Science.